CRSP vs BEAM
CRSP and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $4.97B | $2.81B |
| P/B | — | 2.64 |
| P/S | 1415.8x | 20.1x |
| Revenue | — | $156.03M(TTM) |
| Revenue growth (YoY) | -90.6% | 120.0% |
| Net income | — | -$86.52M(TTM) |
| Earnings growth (YoY) | -58.8% | 78.8% |
| EPS, diluted | — | $-0.69(TTM) |
| EBIT margin | -18933.6% | -274.6% |
| ROE | -33.3% | -7.5% |
| ROIC | -32.6% | -40.5% |
| 1y total return | -15.9% | +14.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: CRSP vs BEAM
| Metric | CRSP | BEAM |
|---|---|---|
| End value | $9.5K | $14.5K |
| Total return | -5.4% | +45.2% |
| CAGR | -0.8% | +5.7% |
| Volatility | 61.6% | 79.6% |
| Sharpe | 0.22 | 0.41 |
| Sortino | 0.34 | 0.63 |
| Max drawdown | -85.1% | -89.1% |
Based on 1693 common trading days, 2020-02-06 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)